← All trials
NCT04943692
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2021
- Primary completion
- Aug 31, 2021
- Completion date
- Aug 31, 2021
- First posted
- Jun 29, 2021
- Last posted
- Jun 29, 2021
- Enrollment
- 500
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Laboratorios Silanes S.A. de C.V.Lead sponsor
- University of GuadalajaraOverall official - principal investigator
- Centro de Investigación Médica Aguascalientes (Red OSMO)Overall official - principal investigator
- Clinica integral del paciente diabético y obesoOverall official - principal investigator
- Clínica Villa Coapa La Vereda S.C.Overall official - principal investigator
- Hospital Hispanos S.A. de C.V.Overall official - principal investigator
- Investigación Biomédica para el Desarrollo de Fármacos S.A. de C.V. (BIOMED-GDL)Overall official - principal investigator
- Mérida Investigación ClínicaOverall official - principal investigator
- Oncológico Potosino (Red OSMO)Overall official - principal investigator
- Universidad Autonoma de Nuevo LeonOverall official - principal investigator
- Resultados médicos, desarrollo e investigación SC (REMEDI)Overall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.